%0 Journal Article
%T A phase IV study of homoharringtonine, cytarabine, aclacinomycin and G-CSF (HCAG) regimen compared with traditional IA regimen in the treatment of newly diagnosed elderly acute myeloid leukemia patients#br#<br>A phase IV study of homoharringtonine, cytarabine, aclacinomycin and G-CSF (HCAG) regimen compared with traditional IA regimen in the treatment of newly diagnosed elderly acute myeloid leukemia patients
%A LIU Zhao
%A ZHANG Yun-xiang
%A WANG Li-ning
%A XIA Zheng
%A MAO Yuan-fei
%A ZHAO Hui-ji&lt
%A br&gt
%A LIU Zhao
%A ZHANG Yun-xiang
%A WANG Li-ning
%A XIA Zheng
%A MAO Yuan-fei
%A ZHAO Hui-jin
%A YOU Jian-hua
%A YU Yang
%A ZHAO Yu-bing
%A REN Yu-hong
%A LI Ya
%A WANG Yan
%A CHEN Qiu-sheng
%A LI Jun-min#
%A CHEN Yu#
%J 上海交通大学学报（医学版）
%D 2017
%R 10.3969/j.issn.1674-8115.2017.08.010
%X Objective · To compare the efficacy and prognostic factors of HCAG regimen with traditional IA regimen in the treatment of newly diagnosed elderly acute myeloid leukemia (AML) patients. Methods · Forty-one patients with AML (aged 55-71 years) were randomly divided into two groups (Group HCAG and Group IA) between 2014 and 2016 for induction and consolidation therapy. Multivariate analysis was applied to identify prognostic factors for relapse-free survival (RFS). Results · A total of 29 patients (70.7%) achieved complete remission (CR). The estimated 2-year overall survival (OS) was 66.8% in Group HCAG and 75.4% in Group IA (P=0.913). The estimated 2-year RFS was 61.8% in Group HCAG and 49.1% in Group IA (P=0.411). Age remained as the unfavorable prognostic factor, leading to significant differences in OS and RFS. In addition, RFS was influenced by cytogenetic/molecular risk stratification. Conclusion · Although HCAG seemed not to particularly benefit the group, the dose reduction of anthracyclines may be applied in elderly patients with comparable short-time outcome. Furthermore, the introduction of homoharringtonine resulted in an improvement of treatment response for more than 20% compared with CAG regimen.<br>： Objective · To compare the efficacy and prognostic factors of HCAG regimen with traditional IA regimen in the treatment of newly diagnosed elderly acute myeloid leukemia (AML) patients. Methods · Forty-one patients with AML (aged 55-71 years) were randomly divided into two groups (Group HCAG and Group IA) between 2014 and 2016 for induction and consolidation therapy. Multivariate analysis was applied to identify prognostic factors for relapse-free survival (RFS). Results · A total of 29 patients (70.7%) achieved complete remission (CR). The estimated 2-year overall survival (OS) was 66.8% in Group HCAG and 75.4% in Group IA (P=0.913). The estimated 2-year RFS was 61.8% in Group HCAG and 49.1% in Group IA (P=0.411). Age remained as the unfavorable prognostic factor, leading to significant differences in OS and RFS. In addition, RFS was influenced by cytogenetic/molecular risk stratification. Conclusion · Although HCAG seemed not to particularly benefit the group, the dose reduction of anthracyclines may be applied in elderly patients with comparable short-time outcome. Furthermore, the introduction of homoharringtonine resulted in an improvement of treatment response for more than 20% compared with CAG regimen
%K homoharringtonine
%K long-term survival
%K risk factors
%K acute myeloid leukemia
%K elderly patient
%K &lt
%K br&gt
%K homoharringtonine
%K long-term survival
%K risk factors
%K acute myeloid leukemia
%K elderly patient
%U http://xuebao.shsmu.edu.cn/CN/abstract/abstract11641.shtml